[HTML][HTML] A novel model for predicting hepatocellular carcinoma development in patients with chronic hepatitis B and normal alanine aminotransferase levels
Gut and Liver, 2017•ncbi.nlm.nih.gov
Methods A simple HCC risk score was developed from 971 patients with CHB who had
elevated hepatitis B virus DNA levels (> 2,000 IU/mL) with normal or mildly elevated ALT
levels (< 80 U/L). The score was validated from an independent cohort of 507 patients.
Results A 4-point risk scale was developed, with HCC risk ranging from 0% to 17.8% at 5
years for the lowest and highest risk scores. The D 2 AS score had high area under the
receiver operating curves (AUROCs) for predicting development of HCC at 3/5 years …
elevated hepatitis B virus DNA levels (> 2,000 IU/mL) with normal or mildly elevated ALT
levels (< 80 U/L). The score was validated from an independent cohort of 507 patients.
Results A 4-point risk scale was developed, with HCC risk ranging from 0% to 17.8% at 5
years for the lowest and highest risk scores. The D 2 AS score had high area under the
receiver operating curves (AUROCs) for predicting development of HCC at 3/5 years …
Methods
A simple HCC risk score was developed from 971 patients with CHB who had elevated hepatitis B virus DNA levels (> 2,000 IU/mL) with normal or mildly elevated ALT levels (< 80 U/L). The score was validated from an independent cohort of 507 patients.
Results
A 4-point risk scale was developed, with HCC risk ranging from 0% to 17.8% at 5 years for the lowest and highest risk scores. The D 2 AS score had high area under the receiver operating curves (AUROCs) for predicting development of HCC at 3/5 years (0.895/0.884). The calculated AUROCs to predict the development of HCC at 3/5 years were 0.889/0.876 in the validation cohort, with 5-year HCC incidence rates ranging from 0% to 13.8% at 5 years for the lowest and highest risk scores.
Conclusions
The D 2 AS risk score can play a valuable role in risk stratification and may be useful for guiding clinical decisions for enhanced surveillance or treatment to reduce the HCC risk in CHB patients with normal or mildly elevated ALT levels.
ncbi.nlm.nih.gov